Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06357221 · ClinicalTrials.gov registry record · Phase 4
A Study to Assess Efficacy and Tolerability of Topical Skincare Products on Psoriasis Patients
A Phase 4 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 4
- Development phase
- 46
- Enrollment target
NCT06357221 is a Phase 4 study that has completed, run by Galderma R&D. The registered enrollment target is 46 participants.
The verdict
NCT06357221, a Phase 4 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 46 participants
- Enrollment target
Study Summary
Subjects having mild-to-severe plaque psoriasis, with active target lesion plaques, and currently on or starting a prescription treatment for plaque psoriasis will apply a topical skincare regimen to one side of the body. Evaluations of the regimen's efficacy will be conducted at 2 weeks, 4 weeks, and 8 weeks post-baseline.
Interventions
- DRUG Cetaphil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2024-04-08 |
| Est. Completion | 2024-07-18 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06357221
The ClinicalTrials.gov registry entry for NCT06357221 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cetaphil is the first listed.
NCT06357221 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06357221 about?
NCT06357221 is a clinical study titled "A Study to Assess Efficacy and Tolerability of Topical Skincare Products on Psoriasis Patients". Subjects having mild-to-severe plaque psoriasis, with active target lesion plaques, and currently on or starting a prescription treatment for plaque psoriasis will apply a topical skincare regimen to one side of the body. Evaluations of the regimen's efficacy will be conducted at 2 weeks, 4 weeks, a...
What is the current status of trial NCT06357221?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 46 participants. The study started on 2024-04-08. Estimated completion is 2024-07-18.
What interventions are being tested in trial NCT06357221?
The interventions under investigation include: Cetaphil (DRUG).
Who is sponsoring clinical trial NCT06357221?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.